This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Malaria	Plasmodium cytochrome bcl	<p>Mouse and cell culture studies suggest the 4(1H)-quinolone-3-diarylether ELQ-300 could help treat liver- and blood-stage malaria infections. In a panel of <i>Plasmodium falciparum</i> and <i>P. vivax</i> clinical isolates, including those that were drug resistant, ELQ-300 showed antiplasmodial activity with single-digit nanomolar IC₅₀ values. In mouse models for blood- and liver-stage <i>P. berghei</i> or <i>P. yoelii</i> infection, oral treatment with ELQ-300 decreased parasitemia and levels of liver-stage parasites compared with vehicle treatment. Next steps could include evaluating ELQ-300 in nonhuman primate models for malaria infection.</p> <p>Medicines for Malaria Venture has ELQ-300 in preclinical development.</p> <p>SciBX 6(13); doi:10.1038/scibx.2013.313 Published online April 4, 2013</p>	Patent applications filed; licensing status unavailable	<p>Nilsen, A. <i>et al. Sci. Transl. Med.</i>; published online March 20, 2013; doi:10.1126/scitranslmed.3005029 Contact: Michael K. Riscoe, Portland VA Medical Center, Portland, Ore. e-mail: riscoem@ohsu.edu Contact: Roman Manetsch, University of South Florida, Tampa, Fla. e-mail: manetsch@usf.edu</p>